Publications by authors named "L C Gaudernack"
Background: Prolonged labor is a common condition associated with maternal and perinatal complications. The standard treatment with oxytocin for augmentation of labor increases the risk of adverse outcomes. Hyoscine butylbromide is a spasmolytic drug with few side effects shown to shorten labor when used in a general population of laboring women.
View Article and Find Full Text PDFArticle Synopsis
- First-time mothers often experience prolonged labor, which can affect about 20% of them and lead to negative birth outcomes; oxytocin is commonly used but has drawbacks.
- This study aims to determine if the antispasmodic drug butylscopolamine bromide (Buscopan®) can effectively shorten labor duration for first-time mothers who show signs of slow progress, as assessed by the World Health Organization partograph.
- Conducted at Oslo University Hospital, the trial will involve 250 women, comparing the effects of butylscopolamine to a placebo on labor duration, pain levels, need for oxytocin, delivery method, and overall maternal experience.
Background: Prolonged labor might contribute to a negative birth experience and influence first-time mothers' attitudes towards future pregnancies. Previous studies have not adjusted for possible confounding factors, such as operative delivery, induction and postpartum hemorrhage. We aimed to determine the impact of prolonged labor on birth experience and a wish for cesarean section in subsequent pregnancies.
View Article and Find Full Text PDFBackground: The use of synthetic oxytocin for augmentation of labor is rapidly increasing worldwide. Hyper-stimulation is the most significant side effect, which may cause fetal distress and operative delivery. We performed an intervention consisting of an educational program and modified guidelines to achieve a more appropriate use of oxytocin.
View Article and Find Full Text PDFBackground: Since Misoprostol Vaginal Insert (MVI - Misodel ®) was approved for labor induction in Europe in 2013, to date, no study has been published comparing MVI to Misoprostol vaginal tablets (MVT). The aim of this study, performed as part of a quality improvement project, was to compare the efficacy and safety of 200 μg MVI versus 25 μg MVT for labor induction in nulliparous women.
Methods: This retrospective cohort study included 171 nulliparous singleton term deliveries induced with MVI (n = 85) versus MVT (n = 86) at Oslo University Hospital Rikshospitalet, Norway, from November 2014 to December 2015.